MedTrace Logo

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

NCT00668642 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-08-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Conditions

Interventions

DRUG

Dutasteride

0.5 mg capsule given orally on daily basis

DRUG

Placebo

Identical placebo

Sponsors & Collaborators

Principal Investigators

  • Daniel H Shevrin, MD · Endeavor Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668642 on ClinicalTrials.gov